🇺🇸 FDA
Pipeline program

BEAM-101

BTX-AUT-001

Phase 2 mab active

Quick answer

BEAM-101 for Sickle Cell Disease is a Phase 2 program (mab) at Beam Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Beam Therapeutics
Indication
Sickle Cell Disease
Phase
Phase 2
Modality
mab
Status
active

Clinical trials